American Century Companies Inc. Decreases Stake in Altimmune, Inc. (NASDAQ:ALT)

American Century Companies Inc. cut its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 83.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,193 shares of the company’s stock after selling 65,461 shares during the period. American Century Companies Inc.’s holdings in Altimmune were worth $88,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Lighthouse Investment Partners LLC acquired a new stake in shares of Altimmune during the fourth quarter worth approximately $4,493,000. Pennant Investors LP acquired a new position in Altimmune during the 4th quarter worth $1,235,000. Gerber LLC bought a new stake in shares of Altimmune in the 4th quarter worth about $2,878,000. Commonwealth Equity Services LLC raised its stake in shares of Altimmune by 31.5% in the 1st quarter. Commonwealth Equity Services LLC now owns 79,945 shares of the company’s stock valued at $814,000 after purchasing an additional 19,172 shares in the last quarter. Finally, North Star Investment Management Corp. acquired a new stake in shares of Altimmune in the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Up 1.3 %

Shares of Altimmune stock opened at $6.23 on Friday. The stock has a market capitalization of $441.72 million, a price-to-earnings ratio of -3.92 and a beta of 0.08. Altimmune, Inc. has a twelve month low of $2.09 and a twelve month high of $14.84. The business’s 50 day simple moving average is $6.65 and its 200-day simple moving average is $7.17.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. During the same period in the prior year, the firm posted ($0.32) EPS. Sell-side analysts predict that Altimmune, Inc. will post -0.54 earnings per share for the current year.

Insider Buying and Selling

In other Altimmune news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares of the company’s stock, valued at $289,510.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ALT. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. Piper Sandler reiterated an “overweight” rating and issued a $25.00 target price on shares of Altimmune in a research report on Friday, June 21st. Evercore ISI raised Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Finally, B. Riley restated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research note on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.80.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.